FGEN RSI Chart
Last 7 days
5.2%
Last 30 days
-6.1%
Last 90 days
-43.8%
Trailing 12 Months
-93%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 167.5M | 0 | 0 | 0 |
2023 | 116.1M | 130.6M | 155.0M | 147.8M |
2022 | 257.7M | 263.1M | 122.9M | 140.7M |
2021 | 191.1M | 205.8M | 220.6M | 235.3M |
2020 | 257.1M | 108.4M | 119.3M | 176.3M |
2019 | 204.9M | 352.5M | 356.7M | 256.6M |
2018 | 133.5M | 147.2M | 135.6M | 213.0M |
2017 | 184.3M | 125.3M | 135.8M | 131.0M |
2016 | 192.8M | 161.5M | 172.1M | 183.2M |
2015 | 136.0M | 166.6M | 172.5M | 180.8M |
2014 | 111.0M | 119.9M | 128.7M | 137.6M |
2013 | 0 | 0 | 0 | 102.2M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 01, 2024 | wettig thane | sold (taxes) | -24,382 | 1.17 | -20,840 | ceo |
Mar 22, 2024 | wettig thane | sold (taxes) | -2,017 | 2.58 | -782 | ceo |
Mar 07, 2024 | wettig thane | bought | 95,470 | 1.9094 | 50,000 | ceo |
Mar 07, 2024 | graham juan | sold (taxes) | -2,113 | 1.79 | -1,181 | chief financial officer |
Mar 06, 2024 | chung christine | acquired | - | - | 781 | svp, china operations |
Mar 06, 2024 | wettig thane | sold (taxes) | -8,480 | 1.87 | -4,535 | ceo |
Mar 06, 2024 | wettig thane | acquired | - | - | 781 | ceo |
Mar 06, 2024 | chung christine | sold (taxes) | -44,113 | 1.87 | -23,590 | svp, china operations |
Mar 06, 2024 | graham juan | acquired | - | - | 781 | chief financial officer |
Mar 06, 2024 | graham juan | sold (taxes) | -38,800 | 1.87 | -20,749 | chief financial officer |
Which funds bought or sold FGEN recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 10, 2024 | CIBC Private Wealth Group, LLC | new | - | 16,935 | 16,935 | -% |
May 10, 2024 | ACADIAN ASSET MANAGEMENT LLC | added | 1.42 | 3,696,000 | 5,883,000 | 0.02% |
May 10, 2024 | MACKENZIE FINANCIAL CORP | reduced | -48.61 | 15,833 | 59,483 | -% |
May 10, 2024 | GROUP ONE TRADING, L.P. | new | - | 191,344 | 191,344 | -% |
May 10, 2024 | BlackRock Inc. | reduced | -3.29 | 9,988,550 | 16,374,600 | -% |
May 10, 2024 | VANGUARD GROUP INC | reduced | -8.62 | 8,883,540 | 15,126,800 | -% |
May 10, 2024 | OSAIC HOLDINGS, INC. | added | 239 | 9,961 | 11,282 | -% |
May 10, 2024 | PNC Financial Services Group, Inc. | unchanged | - | 883 | 1,417 | -% |
May 10, 2024 | LPL Financial LLC | new | - | 26,358 | 26,358 | -% |
May 10, 2024 | JPMORGAN CHASE & CO | added | 63.97 | 178,405 | 231,700 | -% |
Unveiling FibroGen Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to FibroGen Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 48.2B | 6.8B | -8.07 | 7.03 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 19.0B | 2.0B | -57.12 | 9.47 | ||||
BMRN | 15.3B | 2.5B | 74.39 | 6.18 | ||||
INCY | 12.9B | 3.8B | 17.35 | 3.43 | ||||
MID-CAP | ||||||||
BBIO | 5.3B | 107.9M | -9.76 | 48.09 | ||||
APLS | 5.2B | 524.1M | -12.51 | 9.96 | ||||
AXSM | 3.6B | 251.0M | -12.12 | 14.31 | ||||
ARWR | 2.7B | 240.7M | -5.82 | 12.77 | ||||
ACAD | 2.5B | 813.8M | -1.5K | 3.08 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.44 | 4.66 | ||||
NVAX | 1.8B | 996.6M | -4.62 | 1.85 | ||||
CRBP | 458.7M | 881.7K | -13.59 | 481.06 | ||||
INO | 294.6M | 4.9M | -2.36 | 60.54 | ||||
IBIO | 15.6M | 2.1M | -0.67 | 7.61 |
FibroGen Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 106.0% | 55,902,000 | 27,138,000 | 40,134,000 | 44,319,000 | 36,161,000 | 34,366,500 | 15,735,000 | 29,806,000 | 60,827,000 | 16,543,000 | 155,973,000 | 24,364,000 | 44,681,250 | 64,998,500 | 44,032,000 | 42,888,000 | 24,401,000 | 7,974,000 | 33,174,000 | 191,566,000 | 23,863,000 |
Cost Of Revenue | 376.3% | 25,753,000 | 5,406,500 | 4,243,000 | 5,708,000 | 3,491,000 | 4,925,000 | 4,308,000 | 6,809,000 | 4,238,000 | 3,125,500 | 3,266,000 | 3,078,000 | 3,401,000 | - | 2,207,000 | - | - | - | - | - | - |
Costs and Expenses | 6.9% | 86,965,000 | 81,332,500 | 103,616,000 | 132,367,000 | 112,252,000 | 100,518,000 | 109,392,000 | 108,030,000 | 123,820,000 | 151,784,500 | 104,999,000 | 158,199,000 | 108,856,000 | - | 11,702,000 | - | - | - | - | - | - |
Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 158,199,000 | 108,856,000 | 122,997,000 | 11,702,000 | 128,025,000 | 105,475,000 | 108,410,000 | 86,028,000 | 78,747,000 | 72,706,000 |
S&GA Expenses | -5.8% | 22,820,000 | 24,223,000 | 25,573,000 | 31,181,000 | 34,275,000 | 33,965,000 | 29,902,000 | 30,258,000 | 30,564,000 | 34,739,000 | 25,853,000 | 32,554,000 | 30,779,000 | 42,249,000 | -48,981,000 | 63,535,000 | 49,603,000 | 50,707,000 | 35,823,000 | 26,739,000 | 22,210,000 |
R&D Expenses | -25.7% | 38,392,000 | 51,703,000 | 61,194,000 | 95,478,000 | 74,486,000 | 61,628,000 | 75,182,000 | 70,963,000 | 89,018,000 | 113,920,000 | 75,880,000 | 122,567,000 | 74,676,000 | 78,132,000 | 58,476,000 | 61,414,000 | 54,902,000 | 56,798,000 | 49,963,000 | 52,008,000 | 50,496,000 |
EBITDA Margin | 27.5% | -1.29 | -1.77 | -1.77 | -2.35 | -2.54 | -2.01 | -2.87 | -0.80 | -1.06 | -1.19 | -0.92 | -1.06 | - | - | - | - | - | - | - | - | - |
Interest Expenses | -1.4% | 4,996,000 | 5,068,500 | 5,022,000 | 3,069,000 | 2,372,000 | 1,118,500 | 84,000 | 141,000 | 97,000 | 110,000 | 109,000 | 355,000 | 501,000 | 538,000 | 580,000 | 651,000 | 633,000 | 667,500 | 702,000 | 736,000 | 770,000 |
Income Taxes | -58.7% | 33,000 | 80,000 | 84,000 | -235,000 | 74,000 | 108,000 | 114,000 | 23,000 | 113,000 | 111,000 | 106,000 | -3,000 | 134,000 | 170,000 | 215,000 | 169,000 | -194,000 | 72,000 | 76,000 | 205,000 | -25,000 |
Earnings Before Taxes | 41.0% | -33,489,000 | -56,767,000 | -64,208,000 | -88,465,000 | -77,427,000 | -66,347,500 | -91,943,000 | -73,166,000 | -63,412,000 | -134,310,000 | 49,562,000 | -134,553,000 | -71,381,000 | -58,275,000 | 33,232,000 | -85,144,000 | -78,542,000 | -98,051,000 | -49,363,000 | 116,208,000 | -45,436,000 |
EBT Margin | 25.3% | -1.45 | -1.94 | -1.91 | -2.48 | -2.66 | -2.10 | -2.95 | -0.84 | -1.10 | -1.24 | -0.97 | -1.12 | - | - | - | - | - | - | - | - | - |
Net Income | 41.4% | -32,933,000 | -56,232,000 | -63,615,000 | -87,680,000 | -76,705,000 | -66,175,000 | -91,650,000 | -72,624,000 | -63,205,000 | -134,078,000 | 49,798,000 | -133,988,000 | -71,755,000 | -58,634,000 | 33,004,000 | -85,313,000 | -78,348,000 | -98,123,000 | -49,439,000 | 116,003,000 | -45,411,000 |
Net Income Margin | 25.4% | -1.44 | -1.92 | -1.90 | -2.47 | -2.65 | -2.09 | -2.94 | -0.84 | -1.09 | -1.23 | -0.97 | -1.12 | - | - | - | - | - | - | - | - | - |
Free Cashflow | -219.4% | -59,317,000 | -18,572,000 | -85,222,000 | -111,564,000 | -102,182,000 | -52,846,000 | -52,745,000 | -33,969,000 | -10,114,000 | -56,356,000 | 42,680,000 | -28,240,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -13.6% | 366 | 424 | 460 | 515 | 539 | 610 | 609 | 687 | 746 | 774 | 851 | 809 | 787 | 827 | 812 | 808 | 824 | 857 | 894 | 915 | 812 |
Current Assets | -16.1% | 278 | 332 | 364 | 411 | 431 | 493 | 474 | 521 | 524 | 474 | 573 | 564 | 622 | 755 | 737 | 727 | 736 | 702 | 786 | 806 | 579 |
Cash Equivalents | -7.0% | 106 | 114 | 121 | 153 | 189 | 156 | 156 | 168 | 186 | 171 | 275 | 353 | 434 | 678 | 532 | 429 | 122 | 126 | 197 | 75.00 | 82.00 |
Inventory | -34.2% | 27.00 | 42.00 | 41.00 | 41.00 | 42.00 | 40.00 | 40.00 | 41.00 | 43.00 | 31.00 | 29.00 | 25.00 | 21.00 | 17.00 | 12.00 | 9.00 | 8.00 | 7.00 | 5.00 | 2.00 | - |
Net PPE | -7.3% | 12.00 | 13.00 | 15.00 | 17.00 | 19.00 | 21.00 | 22.00 | 25.00 | 27.00 | 28.00 | 29.00 | 31.00 | 31.00 | 34.00 | 36.00 | 37.00 | 40.00 | 43.00 | 43.00 | 45.00 | 46.00 |
Liabilities | -5.8% | 552 | 586 | 576 | 575 | 567 | 612 | 563 | 563 | 568 | 545 | 505 | 529 | 397 | 385 | 341 | 393 | 347 | 322 | 280 | 267 | 304 |
Current Liabilities | -9.6% | 197 | 218 | 209 | 194 | 255 | 274 | 252 | 240 | 255 | 225 | 209 | 233 | 167 | 163 | 118 | 78.00 | 66.00 | 103 | 87.00 | 83.00 | 94.00 |
Shareholder's Equity | -13.0% | -207 | -183 | - | - | -28.88 | -1.48 | 46.00 | 124 | 178 | 229 | 345 | 280 | 390 | 441 | 471 | 415 | 478 | 535 | 614 | 648 | 508 |
Retained Earnings | -1.8% | -1,874 | -1,841 | -1,785 | -1,722 | -1,634 | -1,557 | -1,491 | -1,399 | -1,327 | -1,264 | -1,129 | -1,179 | -1,045 | -974 | -915 | -948 | -863 | -784 | -686 | -637 | -753 |
Additional Paid-In Capital | 0.5% | 1,652 | 1,644 | 1,634 | 1,625 | 1,589 | 1,541 | 1,524 | 1,510 | 1,491 | 1,476 | 1,459 | 1,444 | 1,420 | 1,400 | 1,370 | 1,345 | 1,319 | 1,301 | 1,280 | 1,266 | 1,242 |
Shares Outstanding | 0.7% | 99.00 | 99.00 | 98.00 | 98.00 | 97.00 | 94.00 | 93.00 | 93.00 | 93.00 | 92.00 | 93.00 | 92.00 | - | - | - | - | - | - | - | - | - |
Minority Interest | - | - | - | - | - | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 |
Float | - | - | - | - | 262 | - | - | - | 975 | - | - | - | 1,447 | - | - | - | 2,128 | - | - | - | 2,464 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -223.6% | -59,288 | -18,321 | -84,538 | -110,571 | -101,591 | -52,513 | -51,880 | -33,064 | -8,476 | -54,960 | 44,255 | -26,543 | -44,984 | -7,228 | -1,349 | 149,665 | -59,486 | -45,050 | -27,483 | -28,652 | 22,480 |
Share Based Compensation | -5.7% | 8,762 | 9,296 | 9,476 | 15,883 | 16,112 | 16,224 | 15,567 | 16,658 | 17,152 | 17,072 | 15,704 | 19,001 | 19,384 | 20,269 | 17,891 | 17,644 | 16,916 | 17,402 | 14,793 | 17,642 | 16,430 |
Cashflow From Investing | 400.6% | 51,276 | 10,242 | 54,218 | -14,285 | 103,482 | 1,093 | 44,783 | 17,305 | 25,935 | -50,567 | -122,153 | -57,533 | -196,719 | 143,768 | 98,855 | 153,855 | 56,009 | -25,033 | 152,768 | 18,770 | -26,487 |
Cashflow From Financing | 32.9% | -165 | -246 | -22.00 | 91,532 | 31,485 | 48,674 | -1,092 | 2,087 | -2,893 | -31.00 | -833 | 2,381 | -2,080 | 5,659 | 4,225 | 4,649 | -1,190 | -284 | -3,236 | 2,754 | -3,534 |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenue: | ||
Total revenue | $ 55,902 | $ 36,161 |
Operating costs and expenses: | ||
Cost of goods sold | $ 25,753 | $ 3,491 |
Cost, Product and Service [Extensible List] | Product Revenue, Net [Member] | Product Revenue, Net [Member] |
Research and development | $ 38,392 | $ 74,486 |
Selling, general and administrative | 22,820 | 34,275 |
Total operating costs and expenses | 86,965 | 112,252 |
Loss from operations | (31,063) | (76,091) |
Interest and other, net | ||
Interest expense | (4,996) | (2,372) |
Interest income and other income (expenses), net | 2,570 | 1,036 |
Total interest and other, net | (2,426) | (1,336) |
Loss before income taxes | (33,489) | (77,427) |
Provision for income taxes | 33 | 74 |
Investment income in unconsolidated variable interest entity | 589 | 796 |
Net loss | $ (32,933) | $ (76,705) |
Net loss per share - basic | $ (0.33) | $ (0.81) |
Net loss per share - diluted | $ (0.33) | $ (0.81) |
Weighted average number of common shares used to calculate net loss per share: | ||
Basic | 98,982 | 94,691 |
Diluted | 98,982 | 94,691 |
License Revenue [Member] | ||
Revenue: | ||
Total revenue | $ 0 | $ 6,000 |
Development and Other Revenue [Member] | ||
Revenue: | ||
Total revenue | 878 | 3,891 |
Product Revenue, Net [Member] | ||
Revenue: | ||
Total revenue | 30,538 | 24,161 |
Drug Product Revenue, Net [Member] | ||
Revenue: | ||
Total revenue | $ 24,486 | $ 2,109 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 105,734 | $ 113,688 |
Short-term investments | 71,865 | 121,898 |
Accounts receivable, net ($7,122 and $6,079 from related parties) | 37,083 | 12,553 |
Inventories | 27,335 | 41,565 |
Prepaid expenses and other current assets | 36,150 | 41,855 |
Total current assets | 278,167 | 331,559 |
Restricted time deposits | 1,658 | 1,658 |
Property and equipment, net | 12,166 | 13,126 |
Equity method investment in unconsolidated variable interest entity | 5,776 | 5,290 |
Operating lease right-of-use assets | 64,751 | 68,093 |
Other assets | 3,350 | 3,803 |
Total assets | 365,868 | 423,529 |
Current liabilities: | ||
Accounts payable | 4,353 | 17,960 |
Accrued and other current liabilities ($45,870 and $39,814 to a related party) | 164,286 | 172,891 |
Deferred revenue ($7,901 and $7,220 to related parties) | 12,863 | 12,740 |
Operating lease liabilities, current | 15,231 | 14,077 |
Total current liabilities | 196,733 | 217,668 |
Product development obligations | 17,446 | 17,763 |
Deferred revenue, net of current ($2,343 and $9,705 to a related party) | 147,118 | 157,555 |
Operating lease liabilities, non-current | 62,511 | 66,537 |
Senior secured term loan facilities, non-current | 72,213 | 71,934 |
Liability related to sale of future revenues, non-current | 52,216 | 51,413 |
Other long-term liabilities ($2,458 and $656 to a related party) | 3,786 | 2,858 |
Total liabilities | 552,023 | 585,728 |
Commitments and Contingencies (Note 12) | ||
Redeemable non-controlling interests | 21,480 | 21,480 |
Stockholders' deficit: | ||
Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023 | ||
Common stock, $0.01 par value; 225,000 shares authorized at March 31, 2024 and December 31, 2023; 99,474 and 98,770 shares issued and outstanding at March 31, 2024 and December 31, 2023 | 995 | 988 |
Additional paid-in capital | 1,652,243 | 1,643,641 |
Accumulated other comprehensive loss | (6,507) | (6,875) |
Accumulated deficit | (1,874,853) | (1,841,920) |
Total stockholders' deficit attributable to FibroGen | (228,122) | (204,166) |
Nonredeemable non-controlling interests | 20,487 | 20,487 |
Total deficit | (207,635) | (183,679) |
Total liabilities, redeemable non-controlling interests and deficit | $ 365,868 | $ 423,529 |
 | fibrogen.com |
---|---|
 | Biotechnology |
 | 592 |